Interstitial Lung Disease Program Trials

Minocycline Treatment in Patients with Idiopathic Pulmonary Fibrosis - a Pilot Study
A randomized, double-blind, placebo-controlled study to determine the efficacy and safety of minocycline in patients with Idiopathic Pulmonary Fibrosis (IPF). Minocycline could prevent the overgrowth of small blood vessels (angiogenesis) and delay the progression of idiopathic pulmonary fibrosis (IPF). Randomization will be 1:1 active-to-placebo ratio. Duration of study will be 48 weeks.

The INSPIRE Trial: A Study of Interferon gamma-1b for Idiopathic Pulmonary Fibrosis (IPF)
A phase 3, randomized, double-blind, placebo-controlled trial to determine the efficacy and safety of 200 µg of recombinant Interferon gamma-1b administered by subcutaneous (SC) injection, compared with placebo, in patients with IPF. Interferon gamma-1b may improve survival in patients with mild to moderate IPF. Randomization will be 2:1 active-to-placebo ratio. Duration of study will be 2 years active drug or placebo (rescue therapy will be permitted for patients who meet predefined criteria).

Efficacy and safety of oral bosentan in patients with Idiopathic Pulmonary Fibrosis
Endothelin-1 (ET-1) is expressed in a variety of pulmonary pathological conditions including pulmonary vascular disease and pulmonary fibrosis. Bosentan (an oral dual ET-1 receptor antagonist) could delay the progression of idiopathic pulmonary fibrosis (IPF), a condition for which no established treatment is available. The present trial investigates a possible use of bosentan, which is currently approved for the treatment of symptoms of pulmonary arterial hypertension (PAH) to a new category of patients suffering from IPF.

Sildenafil Treatment in Patients with Idiopathic Pulmonary Fibrosis and Pulmonary Hypertension - a Pilot Study
The objective of this study is to demonstrate that a single dose of sildenafil improves exercise capacity in patients with idiopathic pulmonary fibrosis (IPF) and pulmonary hypertension. We believe that this drug will result in an increase in distance walked in subjects with IPF and pulmonary hypertension as compared with placebo. This study was designed as a placebo-controlled study of sildenafil and its effect on distance walked, shortness of breath, and blood oxygenation. Eligible patients will be randomly assigned, in a 1:1 ratio, to receive either sildenafil or placebo.

<< back, top